Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

608.28 -6.51 (-1.06%)
Streaming Delayed Price Updated: 10:18 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
3 Cash-Producing Stocks in Hot Water
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025. 
Via Benzinga
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Upon closing of the deal, 23andMe will be operated as a wholly owned direct or indirect unit of Regeneron and will continue operations as a personal genomics service. 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank. 
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
From 23andMe, Inc.
Via GlobeNewswire
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Exposures Political
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential. 
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
Exposures US Equities
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. 
Via MarketBeat
Topics ETFs Economy Government
Exposures COVID-19 Interest Rates Political
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%... 
Via StockStory
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
Exposures Political
3 of Wall Street’s Favorite Stocks Skating on Thin Ice
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Price Over Earnings Overview: Regeneron Pharmaceuticals
Via Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Exposures Product Safety
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.